ChIP-Seq of myxoid liposarcoma patient-derived xenograft models
In this work, we have used ChIP-Seq to study FUS-DDIT3 binding sites in patient-derived xenograft (PDX) models of myxoid liposarcoma (MLPS) and investigate the possible changes induced by trabectedin treatment. To this aim, we have used two previously characterized MLPS PDX models one responsive to (ML017) and one resistant against trabectedin (ML017ET). Both models were treated with the anticancer agent trabectedin and samples were retrieved following this schema: 24 hours after the first dose, 72 hours after the first dose, and 15 days after the third dose. ChIP-Seq was performed at the baseline (no treatment) and under the three previously defined treatment conditions.